Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib with or without apatinib.
Epistemonikos ID: 10a81d1b7acd2ab2efcefce9772a8375f7e832b1
First added on: May 15, 2024